New generation nonhormonal management for hot flashes
New generation nonhormonal management for hot flashes
复制标题
DOI：
10.3109/09513590.2012.705380
复制
发表时间：
2013-01-01
影响因子：
2
通讯作者：
Ichigo, Satoshi
中科院分区：
文献类型：
--
作者：
Imai, Atsushi;Matsunami, Kazutoshi;Ichigo, Satoshi
潮热在绝经期妇女中非常常见，可能对生活质量产生不利影响。激素治疗（雌激素加或不加雌激素）仍然是潮热的金标准治疗，但对激素治疗风险的担忧导致其下降，并要求对潮热有效的非激素治疗。几种非激素疗法已经在随机安慰剂对照试验中进行了测试，包括非药理学方法和药理学非激素药物。其中，两类非激素药物已被证明可以有效缓解潮热：γ-氨基丁酸（GABA）类似物和选择性5-羟色胺再摄取抑制剂（SSRIs）。本文讨论了较新的非激素类处方治疗潮热的上级疗效与雌激素替代疗法相比，并提供了一些关于使用它们在绝经后和绝经后妇女的建议。
Hot flashes are very common in women in menopause and can have a detrimental effect on quality of life. Hormone therapy (estrogen with or without progestin) remains the gold standard treatment for hot flashes, but concerns for the risk of hormone therapy have resulted in its decline and a demand for nonhormonal treatments with demonstrated efficacy for hot flashes. Several nonhormonal therapies have been tested in randomized placebo-controlled trials including nonpharmacologic approaches and pharmacologic nonhormonal agents. Among them, two classes of nonhormonal medications have been demonstrated to effectively alleviate hot flashes: gamma-aminobutyric acid (GABA) analogs and selective serotonin reuptake inhibitors (SSRIs). This article discusses the superior efficacy of the newer nonhormonal prescriptions for the treatment of hot flashes when compared with estrogen replacement therapy, and provides some recommendations regarding use of them in peri- and postmenopausal women.